Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Camptothecin. Found 14 abstracts

Burtness B, Powell M, Catalano P, Berlin J, Liles DK, Chapman AE, Mitchell E, Benson AB. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. Am J Clin Oncol. 2016 Aug;39(4):340-5.   PMCID: PMC4177955
Hochster HS, Uboha N, Messersmith W, Gold PJ, O Neil BH, Cohen D, Denlinger C, Cohen S, Leichman CG, Leichman L, Lenz HJ. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol. 2015 Jan;75(1):17-23.
Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG. Efficacy Endpoints of Radiation Therapy Group Protocol 0247: A Randomized, Phase 2 Study of Neoadjuvant Radiation Therapy Plus Concurrent Capecitabine and Irinotecan or Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer. International Journal of Radiation Oncology Biology Physics. 2015 Jan;91(1):116-23.   PMCID: 4385459
Thomay AA, Nagorney DM, Cohen SJ, Sigurdson ER, Truty MJ, Burtness B, Hall MJ, Chun YS. Modern chemotherapy mitigates adverse prognostic effect of regional nodal metastases in stage IV colorectal cancer. J Gastrointest Surg. 2014 Jan;18(1):69-74.
Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.[see comment]. Journal of Clinical Oncology. 2006 Sep;24(25):4069-77.
Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ, National Comprehensive Cancer N. Rectal cancer clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2005 Jul;3(4):492-508.
Langer CJ. Irinotecan in advanced lung cancer: focus on North American trials. Oncology (Huntington). 2004 Jun;18(7 Suppl 4):17-28.
Cotteret S, Jaffer ZM, Beeser A, Chernoff J. p21-Activated kinase 5 (Pak5) localizes to mitochondria and inhibits apoptosis by phosphorylating BAD. Mol Cell Biol. 2003 Aug;23(16):5526-39.
Langer CJ. The global role of irinotecan in the treatment of lung cancer: 2003 update. Oncology (Huntingt). 2003 Jul;17(7 Suppl 7):30-40.
Takahashi N, Li W, Banerjee D, Guan Y, Wada-Takahashi Y, Brennan MF, Chou TC, Scotto KW, Bertino JR. Sequence-dependent synergistic cytotoxicity of ET-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res. 2002 Dec;62(23):6909-15.
Jagasia MH, Langer CJ, Johnson DH, Yunus F, Rodgers JS, Schlabach LL, Cohen AG, Shyr Y, Carbone DP, Devore RF. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study. Clin Cancer Res. 2001 Jan;7(1):68-73.
Langer CJ. The emerging world role of irinotecan in lung cancer. Oncology (Huntingt). 2001 Jul;15(7 Suppl 8):15-21.
Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol. 2001 Sep 15;19(18):3801-7.
Langer CJ. The role of new agents in advanced non-small-cell lung carcinoma. Current oncology reports. 2000 Jan;2(1):76-89.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Camptothecin

Camptothecin Antineoplastic Combined Chemotherapy Protocols therapeutic use administration & dosage analogs & derivatives drug therapy Lung Neoplasms Female Aged Survival Analysis pathology Human Neoplasm Staging Cisplatin Male Adult Deoxycytidine Middle Aged Fluorouracil Treatment Outcome Non-Small-Cell Lung Carcinoma Adjuvant Radiotherapy Antineoplastic Agents Non-US Gov't Support Drug Administration Schedule Organoplatinum Compounds effects dt [Drug Therapy] adverse Phytogenic Antineoplastic Agents 7689-03-4 (Camptothecin) metabolism Leucovorin aa [Analogs & Derivatives] Colorectal Neoplasms United States tu [Therapeutic Use] 0 (Antineoplastic Combined Chemotherapy Protocols) Mutation radiotherapy use Survival Rate chemically induced Liver Neoplasms Taxoids 951-77-9 (Deoxycytidine) Disease-Free Survival secondary Apoptosis Drug Dose-Response Relationship Paclitaxel 51-21-8 (Fluorouracil) Vindesine genetics Animal 100286-90-6 (irinotecan) therapeutic Etoposide tu [Therapeutic Rectal Neoplasms methods Lymphatic Metastasis US Gov't Support-PHS Randomized Controlled Trials Japan adverse effects Middle Age pharmacology Drug Synergism Use] ad [Administration & Dosage] Prognosis surgery 80 and over Aged 58-05-9 (Leucovorin) Adjuvant Chemotherapy Galactose Vinblastine Small Cell Carcinoma Subcellular Fractions 0 (Taxoids) Quality of Life Protein Binding 0 (Folfox protocol) Cyclic AMP-Dependent Protein Kinases Phase III Clinical Trials ae [Adverse EC 2-1-1-45 (Thymidylate Synthase) Neoplasm Proteins Cetuximab Age Factors Chemoradiotherapy Risk Factors Topoisomerase I Inhibitors su [Surgery] 33419-42-0 (Etoposide) CA-19-9 Antigen CHO Cells Disease Progression blood Non-US Gov't Research Support Breast Neoplasms COS Cells Clinical Trials cdc42 GTP-Binding Protein Polyacrylamide Gel Electrophoresis P-Glycoprotein mortality Immunohistochemistry Capecitabine Magnetic Resonance Imaging Salvage Therapy Proportional Hazards Models Pancreatic Neoplasms ai [Antagonists & Inhibitors] Gastrointestinal Diseases Young Adult Nude Mice Biological Models ras Proteins therapy Reverse Transcriptase Polymerase Chain Reaction Enoxaparin etiology biosynthesis Genetic Complementation Test drug effects Feasibility Studies Phosphorylation EC 1-3-1-2 (Dihydrouracil Dehydrogenase (NADP)) Radiotherapy Dosage Inhibitory Concentration 50 Neoplastic Gene Expression Regulation Adenocarcinoma Hamsters Cell Survival Thymidine Phosphorylase Fluorescence Microscopy Retrospective Studies Hepatectomy Antineoplastic Antimetabolites Adolescent Thromboembolism Neoplasm Drug Resistance Cultured Tumor Cells Predictive Value of Tests North America Ribonucleotide Reductases Sphingosine 154361-50-9 (capecitabine)
Last updated on Wednesday, February 05, 2020